SILVER SPRING, Md. & STANS, Switzerland--(BUSINESS WIRE)--After completion by mondoBIOTECH (SIX: RARE) of a Phase II study where inhaled Aviptadil was shown to have a unique safety profile and promising signals of long term efficacy over currently approved therapies in patients affected by Pulmonary Arterial Hypertension (PAH), United Therapeutics Corporation’s Lung Rx subsidiary and mondoBIOTECH finalized a global strategic partnership focused on the development of Aviptadil for a range of indications, as for example PAH, Sarcoidosis, Idiopathic Pulmonary Fibrosis (IPF) and Acute Respiratory Distress Syndrome (ARDS). The platform can generate more than 1 billion CHF turnover.
